ATOZET ® contains two active agents, atorvastatin and ezetimibe, which inhibit the pathways pertaining to hepatic synthesis and intestinal absorption of cholesterol, thereby reducing the LDL levels by 50 to 65%. Each active ingredient has proven its effectiveness to significantly reduce the incidence of cardiovascular disease. From a practical point of view, the reimbursement conditions (INAMI/ RIZIV) for this combination pack have been rightly adjusted to the latest European and Belgian recommendations, allowing patients at very high risk to be optimally treated. The combination 'two in one' is also likely to facilitate therapeutic adherence. ATOZET ® is particularly indicated in secondary prevention, in primary prevention, and in patients with a very high SCORE (≥10%), patients with diabetes, or those with familial hypercholesterolemia whose LDL cholesterol levels remain inadequately controlled by statin monotherapy alone.